Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.60 |
| ▸ | MAP2K4 | P45985 | 4/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | ITK | Q08881 | 2/20 | 0.48 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 4/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | TTK | P33981 | 2/20 | 0.46 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1460552 | 0.90 | MAPK1 (0.54) | NTRK1MAPK1ITKAURKATTK | |
| SCHEMBL1460533 | 0.88 | MAPK1 (0.64) | NTRK1LRRK2MAPK1ITKAURKA | |
| SCHEMBL1460842 | 0.88 | MAPK1 (0.52) | NTRK1MAPK1ITKAURKATTK | |
| SCHEMBL4014552 | 0.85 | TTK (0.56) | MAP2K4LRRK2MAPK1ITKAURKA | |
| SCHEMBL6297928 | 0.85 | TTK (0.59) | MAP2K4ITKMAP2K7AURKATTK | |
| SCHEMBL1461732 | 0.85 | AURKA (0.48) | NTRK1MAPK1ITKAURKATTK | |
| SCHEMBL1461810 | 0.85 | ITK (0.57) | NTRK1MAP2K4LRRK2MAPK1ITK | |
| SCHEMBL1461867 | 0.85 | MAPK1 (0.51) | NTRK1MAP2K4LRRK2MAPK1ITK | |
| SCHEMBL1461099 | 0.85 | ITK (0.55) | MAPK1ITKAURKATTKMAPK3 | |
| SCHEMBL1459746 | 0.84 | AURKA (0.50) | MAP2K4MAPK1ITKMAP2K7AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4643910-B2 | — | — | 2011-03-02 | — | — | JP | claimed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | claimed |
| JP-2005533004-A | — | — | 2005-11-04 | — | — | JP | claimed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | claimed |
| EP-1487803-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | claimed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | claimed |
| WO-2003078402-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | claimed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| EP-1487803-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
| WO-2003078402-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | NTRK1 1342/4885MAP2K4 340/4885LRRK2 527/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | NTRK1 1376/4885MAP2K4 328/4885LRRK2 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.